First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome‑Positive Acute Lymphocytic Leukemia

Lisocabtagene Maraleucel (liso‑cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single‑Arm, Multicenter TRANSCEND CLL 004 Study

Epcoritamab + R2 Regimen and Responses in Patients With High‑Risk Follicular Lymphoma, Regardless of POD24 Status

Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra‑High‑Risk (UHR) Cytogenetics: ICARIA‑MM and IKEMA Subgroup Analysis

Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis‑Stimulating Agent (ESA)‑Naive Lower‑Risk Myelodysplastic Syndromes (LR‑MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study

ELARA Trial Update: Long‑Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)

Lisocabtagene Maraleucel (Liso‑Cel) in R/R MCL: Primary Analysis Results From the MCL Cohort of the Single‑Arm, Multicenter, Phase I Seamless Design TRANSCEND NHL 001 Study

Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM‑014 Study

A Phase III, Open‑Label, Randomized Study to Evaluate the Efficacy and Safety of Single‑Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low‑Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM‑3)

Longer Follow‑Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/ Refractory Large B‑Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL‑1 Trial

Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML‑CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

In‑Class Transition (iCT) from Parenteral Bortezomib‑Based Induction to All‑Oral Ixazomib‑Lenalidomide‑ Dexamethasone in Transplant‑Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community‑Based US MM‑6 Study

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

Idecabtagene Vicleucel (ide‑cel) Versus Standard Regimens in Patients With Triple‑Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa‑3, a Phase III Randomized Controlled Trial (RCT)